Nipocalimab for Myasthenia Gravis
Trial Summary
What is the purpose of this trial?
This trial is testing nipocalimab, a medicine that blocks harmful proteins, in people with generalized myasthenia gravis to see if it can reduce their muscle weakness.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Nipocalimab for treating myasthenia gravis?
What makes the drug Nipocalimab unique for treating myasthenia gravis?
Nipocalimab is unique because it targets the neonatal Fc receptor (FcRn), which plays a role in prolonging the lifespan of antibodies that contribute to myasthenia gravis. This approach is different from traditional treatments that use corticosteroids or immunosuppressants, offering a more specific way to reduce harmful antibodies in the body.12567
Eligibility Criteria
Adults with generalized myasthenia gravis (MG) who have a certain level of muscle weakness and can undergo infusions and blood sampling. Women must not be pregnant, and men agree to not donate sperm during the study. Participants should not have had recent thymectomy or MG crisis, nor should they have heart issues or allergies to the trial drug.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Double-blind Placebo-controlled Phase
Participants receive either nipocalimab or placebo via IV infusion every 2 weeks
Open-label Extension (OLE) Phase
Participants who complete the double-blind phase continue to receive nipocalimab every 2 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Nipocalimab (Monoclonal Antibodies)
- Placebo (Other)